Mauna Kea Tech Gets 'BUY' Rating After Major Financial Overhaul

PARIS, France – January 26, 2026 – Mauna Kea Technologies (Euronext Growth: ALMKT), the developer of the Cellvizio® real-time cellular imaging platform, has received a significant vote of confidence from the market. Financial research firm Allinvest Securities has initiated coverage of the company's stock with a 'BUY' recommendation, suggesting a new chapter may be starting for the once-beleaguered medical device maker.

In a newly published study, Allinvest set a price target of €0.20 per share. This represents a potential upside of 54% from the stock's closing price of €0.13 on January 23. The initiation of coverage is a notable development, as it comes just months after Mauna Kea Technologies successfully exited a court-supervised financial restructuring, a detail underscored by the title of Allinvest's report: “Après la sauvegarde, le réveil de la croissance” (After the safeguard proceedings, the rebirth of growth).

This positive outlook from a new analyst firm adds a fresh perspective to the company's valuation and suggests growing optimism about its prospects following a turbulent period.

From Safeguard to Growth

The new analyst rating cannot be understood without the context of the company's recent past. On March 31, 2025, Mauna Kea Technologies entered into safeguard proceedings, a French legal mechanism similar to Chapter 11 bankruptcy protection in the U.S., designed to allow a company to restructure its debts while continuing operations. The move was prompted by a challenging financial situation, with the company's cash runway projected to last only until June 2025.

The primary goal of the proceedings was to create a protective framework to overhaul the company's liabilities and establish a stable financial foundation for future growth. The process culminated on November 12, 2025, when the Paris Commercial Court officially approved a comprehensive safeguard plan. This plan dramatically reshaped the company's balance sheet.

Under the terms of the restructuring, Mauna Kea Technologies slashed its gross debt by 70%, from €40.2 million down to just €12.1 million. A significant portion of this was achieved through a 55% write-off of debt owed to the European Investment Bank (EIB), with the remainder converted to equity or rescheduled for repayment over a decade. The plan also included a crucial capital increase, which ultimately raised €6.1 million, providing the company with sufficient cash flow to operate until the second half of 2027. This financial maneuver not only cleaned up the balance sheet, increasing equity by €7.7 million, but also provided the operational runway needed to focus on its commercial strategy.

A Tale of Two Targets

The initiation by Allinvest Securities brings another voice to the financial analysis of Mauna Kea, but it also highlights a significant divergence in expert opinion. While Allinvest's €0.20 target points to a healthy upside, it is considerably more conservative than the existing price target from research firm Euroland Corporate, which stands at €0.50 per share.

This wide gap in valuation suggests that analysts are weighing the company's potential and its risks very differently. Allinvest's target, established in the immediate aftermath of the restructuring, likely bakes in a degree of caution. Their analysis appears focused on the initial phase of the company's turnaround, rewarding the successful financial cleanup and the nascent signs of a commercial rebound. It represents a vote of confidence in the 'rebirth of growth' but remains tethered to the company's recent history of financial distress.

In contrast, Euroland Corporate's much higher target of €0.50 may reflect a longer-term valuation, one that places a greater emphasis on the disruptive potential of the company's core technology, Cellvizio®. This more bullish outlook might be based on more aggressive assumptions about future market penetration, revenue growth, and the eventual profitability of the platform, looking past the short-term recovery to a future where Cellvizio® is a standard of care. The discrepancy forces investors to consider whether Mauna Kea is a short-term recovery play, as Allinvest's target might suggest, or a long-term technology powerhouse, as Euroland's valuation implies.

The Cellvizio® Engine

At the heart of Mauna Kea's investment case—and the source of analyst optimism—is its unique Cellvizio® technology. The platform is a form of probe and needle-based confocal laser endomicroscopy (p/nCLE), which provides physicians with real-time, microscopic images of tissue in vivo (inside the living body) during medical procedures.

This technology represents a significant leap beyond standard endoscopy, which provides macroscopic views of tissue surfaces. With Cellvizio®, clinicians can visualize cellular structures on the spot, helping them to classify indeterminate areas of concern, guide surgical interventions with microscopic precision, and potentially reduce the need for multiple diagnostic biopsies that must be sent to a lab for analysis. This ability to 'see' at a cellular level in real time has transformative potential across a wide range of specialties, from gastroenterology to pulmonology and urology.

With its financial house now in order, Mauna Kea's management has stated its primary focus is to accelerate the adoption and commercialization of Cellvizio®, particularly in the lucrative U.S. market. Reports from late 2025 already pointed to a 'notable acceleration of activity' in the United States, suggesting the commercial strategy is beginning to bear fruit. The company's path to its stated goal of profitability by 2027 and positive cash flow from 2029 will depend almost entirely on its ability to successfully expand Cellvizio's market penetration and grow its recurring revenue base from single-use probes.